Pharma BD Deal Intelligence
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →ICN announced a three-way split into Ribapharm (ribavirin royalties + R&D), ICN International, and a slimmer ICN Pharmaceuticals; UBS Warburg estimated the…
Within two years of the spin-off, ICN moved to retake Ribapharm — a reversal that critics flagged as evidence the original three-way split had failed to…
The restructuring was driven by activist investor pressure and SEC scrutiny of chairman Milan Panic; the spin-off ultimately set up the entity that became…
Source summaries from our enrichment pipeline; follow links for originals.
All 6 sources with sentiment breakdown →
ICN Pharmaceuticals announced restructuring plan to split into three publicly-traded companies (ICN, Ribapharm with ribavirin royalties, plus international/biomedicals). Driven by activist pressure and chairman Milan Panic SEC issues. Ribapharm IPO'd 2002. Strategically notable corporate transaction.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| ICN Pharmaceuticals Inc. (corporate restructuring) / ICN three-way split (Ribapharm carve-out) (this deal) | 2000 | — | — |
| Pfizer Inc. / BioNTech SE | 2020 | $748M | 100 |
| Gilead Sciences Inc. / Pharmasset Inc. | 2011 | $11.2B | 98 |
| Abbott Laboratories / Alere Inc. | 2016 | $5.8B | 95 |
| bioMerieux SA / BioFire Diagnostics Inc. | 2013 | $485M | 88 |
| Roche Holding AG / Ventana Medical Systems Inc. | 2008 | $3.4B | 88 |
| AstraZeneca PLC / MedImmune Inc. | 2007 | $15.6B | 82 |
← Browse all deals · How we score deals
More: 2000 deals · Infectious Disease deals